Market Closed -
Nasdaq
16:00:00 2024-04-26 EDT
5-day change
1st Jan Change
883.2
USD
-0.84%
-1.52%
+0.56%
Sales 2024 *
13.91B
19.01B
Sales 2025 *
14.86B
20.31B
Capitalization
95.28B
130B
Net income 2024 *
4.32B
5.91B
Net income 2025 *
4.53B
6.19B
EV / Sales 2024 *
6.23
x
Net cash position
2024
*
8.68B
11.86B
Net cash position
2025
*
13.36B
18.26B
EV / Sales 2025 *
5.51
x P/E ratio 2024 *
23.9
x
P/E ratio 2025 *
22.6
x
Employees
13,450
Yield 2024 *
-
Yield 2025 *
-
Free-Float
77.81%
Duration
1 day 1 week 1 month 3 months 6 months 1 year 5 years 10 years
Period
5 minutes 15 minutes 30 minutes 1 hour 1 day 1 week 1 month 1 year
Style
CandleStick End-of-day OHLC Mountain
Dynamic Chart
Regeneron Faces Q1 Seasonality Despite Eylea HD Launch, Oppenheimer Says
04-26
MT
Oppenheimer Adjusts Price Target on Regeneron Pharmaceuticals to $1,175 From $1,125
04-26
MT
Regeneron Pharmaceuticals Receives a Shareholder Proposal from John Chevedden
04-25
CI
Regeneron Sets Crispr-Based Collaboration With Mammoth Biosciences
04-25
DJ
Regeneron and Mammoth Biosciences Collaborate to Pursue Next-Generation Crispr-Based Gene Editing for Multiple Diseases
04-25
CI
Sanofi Q1 profit slips on generic competition, forex effects
04-25
RE
TD Cowen Adjusts Regeneron Pharmaceuticals' Price Target to $1,030 From $1,020, Keeps Buy Rating
04-24
MT
Unity Biotechnology Adds More Patients, Extends Length of Trial of Prospective Macular Edema Treatment
04-23
MT
UBS Adjusts Regeneron Pharmaceuticals Price Target to $1,099 From $1,090, Maintains Buy Rating
04-17
MT
The market is pinning its hopes on earnings reports
04-17
ANALYST RECOMMENDATIONS : Las Vegas Sands, Regeneron, Kinder Morgan, Rivian, Royal Caribbean...
04-17
Regeneron to defend against DOJ complaint on drug-price manipulation
04-15
RE
Regeneron to defend US Justice Department's complaint on drug-pricing manipulation
04-15
RE
Goldman Sachs Adjusts Regeneron Pharmaceuticals Price Target to $1,126 From $1,121, Buy Rating Kept
04-15
MT
Global markets live: Airbus, UBS, KKR, Meta Platforms, Tesla...
04-11
More news
Oppenheimer Adjusts Price Target on Regeneron Pharmaceuticals to $1,175 From $1,125
04-26
MT
TD Cowen Adjusts Regeneron Pharmaceuticals' Price Target to $1,030 From $1,020, Keeps Buy Rating
04-24
MT
UBS Adjusts Regeneron Pharmaceuticals Price Target to $1,099 From $1,090, Maintains Buy Rating
04-17
MT
ANALYST RECOMMENDATIONS : Las Vegas Sands, Regeneron, Kinder Morgan, Rivian, Royal Caribbean...
04-17
Goldman Sachs Adjusts Regeneron Pharmaceuticals Price Target to $1,126 From $1,121, Buy Rating Kept
04-15
MT
More recommendations
1 day -0.84%
1 week -1.52%
Current month -8.24%
1 month -8.34%
3 months -6.05%
6 months +11.51%
Current year +0.56%
More quotes
Managers
Title Age Since
Founder
64
88-01-07
Chief Executive Officer
71
88-01-07
Director of Finance/CFO
54
02-12-31
Members of the board
Title Age Since
Director/Board Member
71
10-11-11
Chief Executive Officer
71
88-01-07
Director/Board Member
82
91-05-31
More insiders
Date
Price
Change
Volume
24-04-26
883.2
-0.84%
505,652
24-04-25
890.7
-1.75%
576,565
24-04-24
906.5
-0.09%
373,718
24-04-23
907.3
+0.80%
341,220
24-04-22
900.2
+0.37%
351,366
Delayed Quote
Nasdaq, April 26, 2024 at 04:00 pm
More quotes
Regeneron Pharmaceuticals, Inc. specializes in research, development, producing, and selling drugs used in treating ophthalmologic and inflammatory diseases and cancers. Net sales break down by type of revenue as follows:
- revenues from product sales (56.6%);
- revenues from collaboration agreements (40.4%): collaboration with Sanofi (58.1% of revenues), Bayer (29.1%) and Roche (12.8%);
- other (3%): primarily revenues from sales of technology licenses and subcontracted research services.
At the end of 2022, the group had a portfolio of approximately 35 products in clinical development.
More about the company
Last Close Price
883.2
USD
Average target price
1,038
USD
Spread / Average Target
+17.54%
Consensus
1st Jan change
Capi.
+0.56% 95.28B -2.31% 103B +1.69% 22.15B -17.37% 21.02B -9.30% 18.15B -41.01% 16.74B -14.85% 16.05B +3.21% 13.68B +33.54% 12.17B -24.71% 8.24B
Bio Therapeutic Drugs
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1